Transgene Biotek Management
Management criteria checks 2/4
Transgene Biotek's CEO is Koteswara Kanuru, appointed in Mar 2020, has a tenure of 4.83 years. directly owns 21.65% of the company’s shares, worth ₹82.18M. The average tenure of the management team and the board of directors is 5.7 years and 7.5 years respectively.
Key information
Koteswara Kanuru
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.8yrs |
| CEO ownership | 21.6% |
| Management average tenure | 5.7yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
CEO
Koteswara Kanuru (82 yo)
4.8yrs
Tenure
Dr. Koteswara Rao Kanuru serves as the Managing Director of Transgene Biotek Limited since March 4, 2020 and served as its Compliance Officer since May 29, 2015. Dr. Kanuru served as the Compliance Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 4.8yrs | no data | 21.65% ₹ 82.2m | |
| Chief Financial Officer | 5.7yrs | ₹456.00k | no data | |
| Company Secretary & Compliance Officer | 5.7yrs | ₹240.00k | no data |
5.7yrs
Average Tenure
Experienced Management: 526139's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 13.3yrs | no data | 21.65% ₹ 82.2m | |
| Non-Executive Independent Woman Director | 9.8yrs | ₹20.00k | no data | |
| Non-Executive Independent Director | 5.2yrs | ₹20.00k | no data | |
| Independent Director | 4.6yrs | ₹20.00k | no data |
7.5yrs
Average Tenure
41yo
Average Age
Experienced Board: 526139's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 00:39 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Transgene Biotek Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|